HomeCompareRMTO vs ABBV

RMTO vs ABBV: Dividend Comparison 2026

RMTO yields 5000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMTO wins by $62217131802825.25M in total portfolio value
10 years
RMTO
RMTO
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full RMTO calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RMTO vs ABBV

📍 RMTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMTOABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMTO + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMTO pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMTO
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RMTO beats the other by $50,882,683,244,271,450,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMTO + ABBV for your $10,000?

RMTO: 50%ABBV: 50%
100% ABBV50/50100% RMTO
Portfolio after 10yr
$31108565901412.73M
Annual income
$29,930,990,143,689,118,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RMTO
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-0.1
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMTO buys
0
ABBV buys
0
No recent congressional trades found for RMTO or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMTOABBV
Forward yield5000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$62217131802825.35M$102.3K
Annual income after 10y$59,861,980,287,378,210,000.00$24,771.77
Total dividends collected$62057786341622.61M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: RMTO vs ABBV ($10,000, DRIP)

YearRMTO PortfolioRMTO Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$510,700$500,000.00$11,550$430.00+$499.1KRMTO
2$24,410,935$23,864,485.98$13,472$627.96+$24.40MRMTO
3$1,092,192,501$1,066,072,800.30$15,906$926.08+$1092.18MRMTO
4$45,746,366,951$44,577,720,975.17$19,071$1,382.55+$45746.35MRMTO
5$1,793,932,828,410$1,744,984,215,772.56$23,302$2,095.81+$1793932.81MRMTO
6$65,871,973,805,320$63,952,465,678,921.49$29,150$3,237.93+$65871973.78MRMTO
7$2,265,146,887,602,700$2,194,663,875,631,007.20$37,536$5,121.41+$2265146887.57MRMTO
8$72,954,689,148,998,180$70,530,981,979,263,280.00$50,079$8,338.38+$72954689148.95MRMTO
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$69,753$14,065.80+$2201076182660.81MRMTO
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$102,337$24,771.77+$62217131802825.25MRMTO

RMTO vs ABBV: Complete Analysis 2026

RMTOStock

RM2 International, Inc. develops, manufactures, and supplies composite pallets and a supply chain service platform to retailers and manufacturers in the United States. It offers reusable smart block pallets with Internet of Things (IoT) sensor technology under the BLOCKPal brand; and RM2 ELIoT IoT technology for traceability and pallet tracking. The company was formerly known as ARC Group Worldwide, Inc. and changed its name to RM2 International, Inc. in June 2023. RM2 International, Inc. was founded in 1987 and is based in Deland, Florida.

Full RMTO Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RMTO vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMTO vs SCHDRMTO vs JEPIRMTO vs ORMTO vs KORMTO vs MAINRMTO vs JNJRMTO vs MRKRMTO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.